双膦酸盐在治疗骨质疏松症中的应用
Bisphosphonates in the treatment of osteoporosis
摘要
一位74岁的女性在家跌倒后髋部转子下骨折被收住入院。她股骨颈的骨密度（bone mineral density，BMD）的T值为-3．2。患者7年前有腕部骨折史，余无殊。患者10年内出现严重骨质疏松性骨折的绝对风险是23％（用WHO在线FRAX计算工具计算所得，
出处
《英国医学杂志中文版》
2012年第6期374-377,共4页
The BMJ Chinese Edition
参考文献20
-
1Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos lnt 2008 ; 19:733-59. 被引量：1
-
2Black D, Cummings S, Karpf D, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996 ;348 : 1535-41. 被引量：1
-
3Harris ST, Watts NB, Genant HK, MeKeever CD, Hangartner T, Keller M, et al. Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. Arandomized controlled trial. JAMA 1999 ;282 : 1344-52. 被引量：1
-
4Reginster JY, Minne H, Sorensen O, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91. 被引量：1
-
5Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk : results from the BONE study. Osteoporos Int 2004 ; 15:792-8. 被引量：1
-
6Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 ;356 : 1809-22. 被引量：1
-
7McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001 ; 344:333-40. 被引量：1
-
8Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-7. 被引量：1
-
9Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci- Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New Engl J Med 2010;362: 1761-71. 被引量：1
-
10National Institute for Health and Clinical Excellence. Osteoporosis- secondary prevention including strontium ranelate. Alendronate, etidronate, fisedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. (Technical appraisal 161. ) 2011. http.//www, nice. org. uk/TA161. 被引量：1
-
1薛玉梅.高龄心房颤动患者的抗凝治疗[J].今日药学,2009,19(4):5-5.
-
2顾佳.再发脊柱骨折的远期风险[J].中华医学杂志,2008,88(6):386-386. 被引量：2
-
3长期应用二磷酸盐预防骨质疏松者骨干骨折风险增加一倍[J].英国医学杂志中文版,2011,14(3):148-149.
-
4长期应用二磷酸盐预防骨质疏松者骨干骨折风险增加一倍[J].中华全科医师杂志,2011,10(9):644-644.
-
5夏维波,李梅.骨质疏松的诊断与鉴别诊断[J].中国实用内科杂志,2011,31(7):507-509. 被引量：8
-
6崔羽,滕斌,程天一,杨菁,张之梁,任华,蔡伟,庞小芬.上海市社区老年人骨质疏松性骨折的风险评估[J].中国骨质疏松杂志,2016,22(7):824-827. 被引量：16
-
7王战建,邸彩霞.α-糖苷酶抑制剂与心血管风险[J].药品评价,2011,8(19):32-36.
-
8苏鹏超,赵继懋,宋健,丰琅,张道新.索非那新联合坦索罗辛治疗前列腺增生伴膀胱过度活动症的有效性Meta分析[J].现代泌尿外科杂志,2015,20(11):794-797. 被引量：8
-
9坚尚（译）.雷洛昔芬与绝经后妇女的血栓和卒中相关[J].中华医学信息导报,2009,24(4):11-11.
-
10杜大勇,赖晓辉,李运田,黄海,李庆勇,柳杨,石丽威,张俊堂.高维持剂量氯吡格雷在冠脉分叉病变双药物洗脱支架植入术后有效性和安全性对照研究[J].山西医科大学学报,2011,42(6):483-487. 被引量：3
